

FINAL - February 16, 2011

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Atlanta, Georgia

February 23-24, 2011

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
<u>Wednesday, February 23, 2011</u>		
8:00 <u>Welcome & Introductions</u>		Dr. Carol Baker (Chair, ACIP) Dr. Larry Pickering (Executive Secretary, ACIP; CDC)
8:30 <u>Pertussis</u>		
· Introduction		Dr. Mark Sawyer (ACIP, WG Chair)
· Brief update on pertussis surveillance 2010	Information	Dr. Jennifer Liang (CDC/NCIRD)
· Proposed recommendations on use of Tdap in healthcare personnel		Dr. Jennifer Liang (CDC/NCIRD)
· Proposed recommendation on use of post-exposure prophylaxis in healthcare personnel	<u>Vote</u>	Dr. Jennifer Liang (CDC/NCIRD)
· Overview of Tdap use during pregnancy		
· Historical perspective and published literature	Information &	Dr. Tejpratap Tiwari (CDC/NCIRD)
· Unpublished and recent data		Dr. Jennifer Liang (CDC/NCIRD)
· Considerations for use of Tdap in pregnant women	Discussion	Dr. Jennifer Liang (CDC/NCIRD)
10:30 <i>Break</i>		
11:00 <u>Japanese Encephalitis Vaccine</u>		
· Introduction	Information & Discussion	Dr. Paul Cieslak (ACIP, WG Chair); Dr. Marc Fischer (CDC/NCEZID)
· Data supporting use of a booster dose		Dr. Katrin Dubischar-Kastner (Intercell)
· Recommendations for use of a booster dose	<u>Vote</u>	Dr. Marc Fischer (CDC/NCEZID)
11:30 <u>Immunization of Healthcare Personnel (HCP)</u>		
· Introduction	Information & Discussion	Ms. Kris Ehresmann (ACIP, WG Chair)
· Immunization of HCP recommendations	<u>Vote</u>	Dr. Harry Keyserling (Emory University School of Medicine)
12:05 <i>Lunch</i>		
1:20 <u>Immunization Safety Office Update: Vaccines and Febrile Seizures</u>		
· Introduction and background	Information	Dr. Frank Destefano (CDC/NCEZID)
· Febrile seizures in the Vaccine Safety Datalink (VSD)		Dr. Grace Lee (Harvard Medical School)
2:20 <u>Influenza</u>		
· Introduction		Dr. Wendy Keitel (ACIP, WG Chair)
· Epidemiology and surveillance update		Dr. Lisa Grohskopf (CDC/NCIRD)
· Vaccine distribution/uptake	Information & Discussion	Dr. Cindy Weinbaum (CDC/NCIRD)
· Antiviral guidance		Dr. Tim Uyeki (CDC/NCIRD)
· Influenza vaccines and egg allergies		Dr. Lisa Grohskopf (CDC/NCIRD)
· Proposed recommendations		Dr. Lisa Grohskopf (CDC/NCIRD)
3:20 <i>Break</i>		
3:40 <u>Herpes Zoster (HZ)</u>		
· Introduction		Dr. Paul Cieslak (ACIP, WG Chair)
· Background regarding HZ and HZ vaccine		Dr. Rafael Harpaz (CDC/NCIRD)
· Field effectiveness of HZ vaccine in persons 60 years of age and older		Dr. Hung Fu Tseng (Southern California Kaiser Permanente)
· Update: HZ vaccine safety: VAERS & VSD data	Information & Discussion	Dr. Zanie Leroy (CDC/NCEZID); Dr. Hung Fu Tseng (SCKP)
· Results of phase 4 safety study of HZ vaccine		Dr. Janie Parrino (Merck)
· Efficacy of HZ vaccine in persons 50-59 years of age		Dr. Janie Parrino (Merck)
· Safety and immunogenicity of HZ vaccine in persons 50-59 years of age		Dr. Janie Parrino (Merck)
5:20 <u>Vaccine Supply</u>	Information	Dr. Jeanne Santoli (CDC/NCIRD)
5:30 <u>Public Comments</u>		
5:45 <u>Adjourn</u>		

FINAL - February 16, 2011

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Atlanta, Georgia

February 23-24, 2011

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
Thursday, February 24.		
8:00 <u>Unfinished Business</u>		Dr. Carol Baker (Chair, ACIP)
8:15 <u>Evidence Based Recommendations</u>		
· Update on EB recommendation implementation	Information	Dr. Jon Temte (ACIP, WG Chair)
8:20 <u>Immunization in the United Kingdom</u>		
· Immunization coverage levels in the United Kingdom	Information	Dr. David Salisbury (Department of Health, United Kingdom)
8:50 <u>Human Papillomavirus Vaccines (HPV)</u>		
· Introduction and HPV epidemiology overview		Dr. Eileen Dunne (CDC/NCHHSTP)
· Update on HPV-related cancers	Information	Dr. Mona Saraiya (CDC/NCCDPHP)
· Anal HPV infection and cancer	&	Dr. Joel Palefsky (UCSF)
· Cost effectiveness updates and review	Discussion	Dr. Harrell Chesson (CDC/NCHHSTP)
· HPV Work Group plans		Dr. Lauri Markowitz (CDC/NCHHSTP)
10:00 <u>Break</u>		
10:30 <u>Hepatitis B Vaccine</u>		
· Update: Work Group activities		Dr. Mark Sawyer (ACIP, WG Chair)
· Update: diabetes mellitus statistics	Information &	Ms. Nilka Burrows (CDC/NCCDPHP)
· Hepatitis B incidence and diabetes mellitus	Discussion	Ms. Meredith Reilly (CDC/NCHHSTP)
· Next steps		Dr. Trudy Murphy (CDC/NCHHSTP)
11:30 <u>13-valent Pneumococcal Conjugate Vaccine (PCV13)</u>		
· Introduction		Dr. Mike Marcy (ACIP, WG Chair)
· Safety and immunogenicity of PCV13 in adults		Dr. Peter Paradiso (Pfizer)
· Cost-effectiveness of PCV13 vaccination of adults ≥50 years of age	Information &	Dr. Richard Zimmerman (University of Pittsburgh), Dr. Kenneth Smith (University of Pittsburgh)
· Public health and economic impact of PCV13 in US adults ≥50 years of age	Discussion	Dr. David Strutton (Pfizer)
1:00 <u>Public comment</u>		
1:15 <u>Adjourn</u>		

Acronyms

HZ	Herpes Zoster
NCCDPHP	National Center for Chronic Disease Prevention and Health
NCEZID	National Center for Emerging and Zoonotic Infectious Diseases
NCHHSTP	National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
NCIRD	National Center for Immunization and Respiratory Diseases
TBD	To be determined
Tdap	Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
UCSF	University of California, San Francisco
VAERS	Vaccine Adverse Event Reporting System
VSD	Vaccine Safety Datalink
WG	Work Group

This document can be found on the CDC website at:

<http://www.cdc.gov/vaccines/recs/acip/downloads/agenda-feb11.pdf>